Subarachnoid hemorrhage

Egret Therapeutics Announces the Addition of Three New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 3, 2023
Hospital, Neuroradiology, Cerebrovascular disease, Patient, Bleeding, Zilkha Neurogenetic Institute, Entrepreneurship, USC, The Society of Neurological Surgeons, Stanford University, Surgery, University, Keck School of Medicine of USC, Physician, Stroke, Society, George Washington University School of Medicine & Health Sciences, Vasospasm, Washington University School of Medicine, Columbia University Vagelos College of Physicians and Surgeons, Surgeon, Neurology, Washington University in St. Louis, Therapy, The Washington Campus Board of Directors, Barnes-Jewish Hospital, Columbia University, Science, Congress, SAB, Subarachnoid hemorrhage, Research, Degenerative disease, United States Air Force Scientific Advisory Board, Pharmaceutical industry, DRS, Neurosurgery

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members:

Key Points: 
  • Egret Therapeutics, a portfolio company of Turret Capital Management, Announces the Addition of Three New Members.
  • In addition to having a busy surgical cerebrovascular practice, he runs a laboratory studying vasospasm.
  • The newly appointed members will work with the company's current SAB and with Egret Therapeutics' leadership team in bringing EGT-101 to the clinic.
  • "We look forward to their contributions as we progress our lead asset EGT-101 into the clinic next year," said Michael Lim, M.D., Chair of Neurological Surgery at Stanford University and Co-Founder and Chair of Egret Therapeutics' Scientific Advisory Board.

Acasti Pharma to Present at Q4 Investor Summit

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Marketing, PHN, Skull, FDA, Risk, Private Securities Litigation Reform Act, Bleeding, Securities Act of 1933, Nerve Damage, Postherpetic neuralgia, SEC, NASDAQ, Brain, Summit, Compliance, Securities Exchange Act of 1934, Company, ACST, Disability, Assam Global Investors' Summit, Neuropathic pain, Subarachnoid hemorrhage, SubArachnoid Space, CEO, TSX, A-T, SAH, Pharmaceutical industry, Security (finance), Ataxia–telangiectasia

LAVAL, Qubec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan DAlvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.

Key Points: 
  • LAVAL, Qubec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan DAlvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.
  • Investors interested in participating in one-on-one meetings should contact Acasti Investor Relations at [email protected] , or their Investor Summit representatives.
  • Acasti is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Retrieved on: 
Monday, November 7, 2022
GLOBE, Marketing, PHN, Skull, FDA, Risk, Telephone, Private Securities Litigation Reform Act, Bleeding, Securities Act of 1933, Nerve Damage, Postherpetic neuralgia, SEC, NASDAQ, Brain, Compliance, Securities Exchange Act of 1934, ACST, Disability, Neuropathic pain, Subarachnoid hemorrhage, SubArachnoid Space, TSX, A-T, SAH, Pharmaceutical industry, Internet service provider, Ataxia–telangiectasia

A webcast of the call may be accessed at https://app.webinar.net/KP8QXdZzj5R or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .

Key Points: 
  • A webcast of the call may be accessed at https://app.webinar.net/KP8QXdZzj5R or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .
  • A webcast replay will be available on the Companys Investors News/Events section of the website ( https://www.acastipharma.com/investors/ ) through November 14, 2023.
  • Acasti is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IRRAS Announces Participation and Educational Symposium at Key Upcoming Neurosurgery Conferences

Retrieved on: 
Wednesday, October 5, 2022
Subarachnoid hemorrhage, CA, Congress, CET, Jean-Louis Vincent, Review, CSF, SAH, Patient, Hospital, Neurocritical Care Society, NCS, Congress of Neurological Surgeons, Health, Awareness, CNS, Lifespan, Nasdaq Stockholm, Neurosurgery, Brain, Poster, Pharmaceutical industry, Medical device, Nightclub

IRRAS will participate in the "Neurotrauma Across the Lifespan and Around the World" symposium at CNS on Sunday, October 9, 2022, beginning at 0800 PDT, which will provide hands-on product training to symposium attendees.

Key Points: 
  • IRRAS will participate in the "Neurotrauma Across the Lifespan and Around the World" symposium at CNS on Sunday, October 9, 2022, beginning at 0800 PDT, which will provide hands-on product training to symposium attendees.
  • Attendees at both conferences are encouraged to visit the IRRAS booths to learn more.
  • In addition to the neurotrauma symposium participation at CNS, clinical data regarding the use of the IRRAflowsystem will also be presented.
  • IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients.

IRRAS Announces Participation and Educational Symposium at Key Upcoming Neurosurgery Conferences

Retrieved on: 
Wednesday, October 5, 2022
Subarachnoid hemorrhage, CA, Congress, CET, Jean-Louis Vincent, Review, CSF, SAH, Patient, Hospital, Neurocritical Care Society, NCS, Congress of Neurological Surgeons, Health, Awareness, CNS, Lifespan, Nasdaq Stockholm, Neurosurgery, Brain, Poster, Pharmaceutical industry, Medical device, Nightclub

IRRAS will participate in the "Neurotrauma Across the Lifespan and Around the World" symposium at CNS on Sunday, October 9, 2022, beginning at 0800 PDT, which will provide hands-on product training to symposium attendees.

Key Points: 
  • IRRAS will participate in the "Neurotrauma Across the Lifespan and Around the World" symposium at CNS on Sunday, October 9, 2022, beginning at 0800 PDT, which will provide hands-on product training to symposium attendees.
  • Attendees at both conferences are encouraged to visit the IRRAS booths to learn more.
  • In addition to the neurotrauma symposium participation at CNS, clinical data regarding the use of the IRRAflowsystem will also be presented.
  • IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients.

Acasti Announces Court Dismissal of Stockholder Litigation

Retrieved on: 
Friday, September 30, 2022
Securities Exchange Act of 1934, Disability, TSX, COVID-19, Mergers and acquisitions, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Acquisition, Compliance, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), District court, GLOBE, Marketing, ACST, Pharmaceutical industry, Ataxia–telangiectasia

The remaining two cases were consolidated before Judge Katherine Polk Failla in the United States District Court for the Southern District of New York.

Key Points: 
  • The remaining two cases were consolidated before Judge Katherine Polk Failla in the United States District Court for the Southern District of New York.
  • Acasti and the individual defendants filed a motion to dismiss on February 25, 2022.
  • Accordingly, subject to any appeal that may be taken in response to todays ruling, all four stockholder suits filed in connection with the Merger have now been dismissed.
  • Acasti is a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Retrieved on: 
Thursday, September 29, 2022
Securities Exchange Act of 1934, Disability, LTIP, Remuneration, Indian stock exchange, TSX, COVID-19, Director, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Company, CDN, Compliance, Special, Cyprus Securities and Exchange Commission, Audit committee, Risk, SAH, Skull, Exercise, Postherpetic neuralgia, SubArachnoid Space, Chair, A-T, Private Securities Litigation Reform Act, KPMG LLP, NASDAQ, Board, Nerve Damage, KPMG, Security (finance), GLOBE, Marketing, ACST, Risk management, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the Meeting) which was held virtually on Wednesday September 28, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the Meeting) which was held virtually on Wednesday September 28, 2022.
  • At the Meeting, shareholders passed an advisory (non-binding) resolution approving the compensation of Acastis named executive officers.
  • At the Meeting, disinterested shareholders approved the amendments described above to the Stock Option Plan and the Equity Incentive Plan.
  • The Governance & Human Resources Committee is now composed of Mr. Donald Olds, Chair, Mr. Vimal Kavuru and Mr. John Canan.

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Retrieved on: 
Wednesday, September 21, 2022
Securities Exchange Act of 1934, Pain scale, Disability, PK, Trial of the century, IV, COVID-19, Blood pressure, Bleeding, FDA, Brain, Phase, PHN, Drug Quality and Security Act, Betamethasone, Subarachnoid hemorrhage, Neuropathic pain, Company, Compliance, Securities Act of 1933, Heredity, Nimodipine, U.S. Securities and Exchange Commission, Patient, Risk, SAH, Skull, Bupivacaine, Postherpetic neuralgia, A-T, Pain, SubArachnoid Space, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Interview, Security (finance), Neurodegeneration, Marketing, ACST, Disease, Fine chemical, Vaccine, Pharmaceutical industry, Ataxia–telangiectasia

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Key Points: 
  • Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.
  • Jolly then asked about one of the Company's additional assets, GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH).
  • "At the end of the day, it's all about getting these drugs approved to treat these rare and orphan diseases."
  • All forward looking statements contained in this press release speak only as of the date on which they were made.

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Retrieved on: 
Wednesday, September 14, 2022
Securities Exchange Act of 1934, Disability, Degenerative disease, TSX, COVID-19, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Company, Compliance, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), Conference, GLOBE, Marketing, ACST, Online gambling, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
  • Management is also planning to participate in a panel at the conference titled "Orphan Drugs: Innovative Companies Addressing Rare Diseases."
  • The panel, also to be conducted virtually, will be held on Wednesday, September 28, 2022 at 2:00pm ET.
  • To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://www.lythampartners.com/fall2022invreg/ .

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Monday, September 12, 2022
Securities Exchange Act of 1934, Disability, TSX, COVID-19, Bleeding, FDA, Brain, PHN, Drug Quality and Security Act, Neuropathic pain, Subarachnoid hemorrhage, Compliance, Securities Act of 1933, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), Conference, GLOBE, Marketing, ACST, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.
  • The webcasted presentation will be available on demand at the H.C. Wainwright Conference Platform for registered guests.
  • To arrange a meeting with management, please contact your H.C. Wainwright representative.
  • Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.